npj Breast Cancer (Sep 2023)
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models
- Lorna Hopcroft,
- Eleanor M. Wigmore,
- Stuart C. Williamson,
- Susana Ros,
- Cath Eberlein,
- Jennifer I. Moss,
- Jelena Urosevic,
- Larissa S. Carnevalli,
- Sara Talbot,
- Lauren Bradshaw,
- Catherine Blaker,
- Sreeharsha Gunda,
- Venetia Owenson,
- Scott Hoffmann,
- Daniel Sutton,
- Stewart Jones,
- Richard J. A. Goodwin,
- Brandon S. Willis,
- Claire Rooney,
- Elza C. de Bruin,
- Simon T. Barry
Affiliations
- Lorna Hopcroft
- Bioscience Early Oncology, AstraZeneca
- Eleanor M. Wigmore
- Early Data Science, Oncology Data Science, AstraZeneca
- Stuart C. Williamson
- Bioscience Early Oncology, AstraZeneca
- Susana Ros
- Bioscience Early Oncology, AstraZeneca
- Cath Eberlein
- Bioscience Early Oncology, AstraZeneca
- Jennifer I. Moss
- Bioscience Early Oncology, AstraZeneca
- Jelena Urosevic
- Bioscience Early Oncology, AstraZeneca
- Larissa S. Carnevalli
- Bioscience Early Oncology, AstraZeneca
- Sara Talbot
- Bioscience Early Oncology, AstraZeneca
- Lauren Bradshaw
- Bioscience Early Oncology, AstraZeneca
- Catherine Blaker
- Bioscience Early Oncology, AstraZeneca
- Sreeharsha Gunda
- Information Technology, AstraZeneca
- Venetia Owenson
- Imaging Sciences, AstraZeneca
- Scott Hoffmann
- Imaging Sciences, AstraZeneca
- Daniel Sutton
- Imaging Sciences, AstraZeneca
- Stewart Jones
- Imaging Sciences, AstraZeneca
- Richard J. A. Goodwin
- Imaging Sciences, AstraZeneca
- Brandon S. Willis
- Bioscience Early Oncology, AstraZeneca
- Claire Rooney
- Translational Medicine, AstraZeneca
- Elza C. de Bruin
- Translational Medicine, AstraZeneca
- Simon T. Barry
- Bioscience Early Oncology, AstraZeneca
- DOI
- https://doi.org/10.1038/s41523-023-00581-8
- Journal volume & issue
-
Vol. 9,
no. 1
pp. 1 – 1
Abstract
No abstracts available.
